Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3878230 | The Journal of Urology | 2008 | 6 Pages |
Abstract
Medial sextant and targeted biopsy directed at transrectal ultrasound identified lesions detects 94.6% of the prostate cancer that is detected with a 10 core biopsy protocol. The latter detects an extra 3% of clinically significant prostate cancer, while increasing costs by 30%. It is important to consider the absolute benefits of systematic lateral prostate biopsy in light of this additional expense when selecting an appropriate transrectal ultrasound biopsy regimen for a patient suspected of harboring prostate cancer.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Mischel G. Neill, Ants Toi, Gina A. Lockwood, Andrew Evans, Lisa Tammsalu, Neil E. Fleshner,